Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Abstract 552-P
Policy decisions on the reimbursement of tirzepatide in individual countries should be based on health technology assessments integrating long-term efficacy and safety clinical data with country-specific cost-utility analyses comparing tirzepatide with other glucose-lowering medications used in clinical practice
Reserve it for moments when a point truly lands and you have no real counter
The inclusion of glucagon receptor agonism introduces some additional theoretical considerations compared with dual agonists
doi:10.1021/nn300934k Chung SK, Kim YC, Takaya Y, Terashima K, Niwa M
FAQS How fast can I see the result
US$ 21.35
US$ 23.59
US$ 27.97
